Nereus Pharmaceuticals, Inc., a drug discovery and development company, engages in the discovery and development of therapeutics for cancer, and inflammatory and infectious diseases. Its products include NPI-2358, a selective tumor vascular disrupting agent evaluated for the treatment of solid tumors and lymphomas; NPI-0052, a proteasome inhibitor evaluated for the treatment of multiple myeloma, solid tumors, lymphomas, and other malignancies; NF-?B, a family of synthetic small molecule diterpenes that regulate NF-?B activation; and IKK, a family of synthetic small molecule diterpene analogues that modulate IKK activity. The company also develops anti-infectives for antibacterial activity and activity against methicillin and vancomycin resistant strains. In addition, it develops drug candidates for the treatment of oncology, infectious diseases, and inflammation. Nereus Pharmaceuticals, Inc. was founded in 1998 and is based in San Diego, California.